Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)

About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months. The few systemic treatment options available only moderately prolong survival. Isolated hepatic perfusion (IHP) with melphalan is a regional treatment option, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Olofsson Bagge, Roger, Nelson, Axel, Shafazand, Amir, All-Eriksson, Charlotta, Cahlin, Christian, Elander, Nils, Helgadottir, Hildur, Kiilgaard, Jens Folke, Kinhult, Sara, Ljuslinder, Ingrid, Mattsson, Jan, Rizell, Magnus, Sternby Eilard, Malin, Ullenhag, Gustav J., Nilsson, Jonas A., Ny, Lars, Lindnér, Per
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414734/
https://www.ncbi.nlm.nih.gov/pubmed/36940407
http://dx.doi.org/10.1200/JCO.22.01705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414734/
https://www.ncbi.nlm.nih.gov/pubmed/36940407
http://dx.doi.org/10.1200/JCO.22.01705

Ejemplares similares